心脏病实践中的胃保护:意大利对处方态度的调查
Salvatore E Aragona1, Alberto Margonato2, Salvatore Felis3
1Unit of Surgery, ASST Melegnano Martesana, Melzo Hospital, Melzo, Milan, Italy.
Minerva cardiology and angiology
|February 13, 2024
概括
意大利心脏病专家优先考虑胃保护,对那些服用对胃有害药物的患者来说. 一项调查显示,这种经验改善了处方实践,特别是在质子抑制剂 (PPI) 方面.
科学领域:
- 胃肠病学 胃肠病学
- 心脏病学 心脏病学
- 临床药房 临床药房
背景情况:
- 对于使用NSAID,抗血小板和抗凝固剂的患者来说,胃的保护至关重要.
- 心脏病专家经常开胃保护剂,以减轻药物诱导的胃损伤.
研究的目的:
- 调查意大利心脏病学家在临床环境中对胃保护的态度和做法.
- 评估调查经验对胃保护剂的处方习惯的影响.
主要方法:
- 一个自我管理的问卷被用来收集三个月内心脏病学家的数据.
- 90名意大利心脏病专家参与了这项调查.
主要成果:
- 所有心脏病专家都考虑了胃保护,对60%的患者开了质子抑制剂 (PPI).
- 调查经验导致重新评估PPI的适当性,并停止不适当的处方.
- 一种新的三重作用医疗器械影响了转向更合适的胃保护策略的转变.
结论:
- 适当的胃保护剂处方具有临床意义.
- 纵向调查的经验改善了PPI的处方实践,并鼓励使用新的多动力胃保护装置.
相关概念视频
Gastroesophageal Reflux Disease II: Clinical Features and Management
85
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
85
Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
122
Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
122
Peptic Ulcer Disease IV: Management
92
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
92
Gastritis III: Clinical Manifestations and Management
251
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
251
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
486
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
486
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
436
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
436


